Saniona received the shares in August 2026, when AstronauTx exercised its option to acquire worldwide rights to ATX0926. The sale does not affect Saniona’s rights under the collaboration, including potential milestone payments of up to USD 172 million and tiered royalties. The transaction is expected to close by the end of November.

The non-dilutive funding will support SAN2465 and SAN2668 as they advance into Phase 1 clinical development. Saniona submitted an IND application to the US FDA for SAN2465, a candidate for major depressive disorder, in October.

“With SAN2465 and SAN2668 approaching clinical development, our priority is to allocate capital to our wholly owned programs,” says Johnny Stilou, CFO of Saniona.

Source: Saniona press release, 10 November 2026 — read the release